Zanzalintinib (XL092)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Zanzalintinib (XL092), covering 2025-08-17 to 2026-04-03. Get the full timeline:
Most recent: Clinical Trial Update: Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC [Phase 2]